$4.74
3.27% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
CA4576375022
Symbol
INM
Sector
Industry

InMed Pharmaceuticals Inc Stock price

$4.74
+0.44 10.23% 1M
-0.56 10.57% 6M
-3.58 43.03% YTD
-3.10 39.54% 1Y
-700.26 99.33% 3Y
-3,039.18 99.84% 5Y
-1,826.76 99.74% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.15 3.27%
ISIN
CA4576375022
Symbol
INM
Sector
Industry

Key metrics

Market capitalization $790.00k
Enterprise Value $-3.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.57
EV/Sales (TTM) EV/Sales -0.76
P/S ratio (TTM) P/S ratio 0.16
P/B ratio (TTM) P/B ratio 0.38
Revenue growth (TTM) Revenue growth 5.17%
Revenue (TTM) Revenue $4.96m
EBIT (operating result TTM) EBIT $-7.53m
Free Cash Flow (TTM) Free Cash Flow $-6.58m
Cash position $5.63m
EPS (TTM) EPS $-14.34
P/S forward 0.15
EV/Sales forward negative
Short interest 0.87%
Show more

Is InMed Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

InMed Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast InMed Pharmaceuticals Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast InMed Pharmaceuticals Inc:

Hold
100%

Financial data from InMed Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.96 4.96
5% 5%
100%
- Direct Costs 4.08 4.08
15% 15%
82%
0.88 0.88
24% 24%
18%
- Selling and Administrative Expenses 4.57 4.57
2% 2%
92%
- Research and Development Expense 3.24 3.24
11% 11%
65%
-6.93 -6.93
0% 0%
-140%
- Depreciation and Amortization 0.60 0.60
3% 3%
12%
EBIT (Operating Income) EBIT -7.53 -7.53
0% 0%
-152%
Net Profit -6.82 -6.82
2% 2%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about InMed Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Eric Adams
Employees 13
Founded 1981
Website www.inmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today